The Latest Analyst Ratings for IGM Biosciences
Portfolio Pulse from Benzinga Insights
In the last quarter, IGM Biosciences (NASDAQ:IGMS) received 3 bullish, 2 somewhat bullish, and 5 indifferent analyst ratings. The average 12-month price target is $24.6, representing a 21.61% decrease from the previous average of $31.38.

June 06, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
IGM Biosciences received mixed analyst ratings in the last quarter, with an average 12-month price target of $24.6, down 21.61% from the previous average.
IGM Biosciences received a mix of bullish, somewhat bullish, and indifferent analyst ratings in the last quarter. The average 12-month price target has decreased by 21.61% from the previous average, which may indicate uncertainty about the company's future performance. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100